<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411527</url>
  </required_header>
  <id_info>
    <org_study_id>KF01282214</org_study_id>
    <nct_id>NCT01411527</nct_id>
  </id_info>
  <brief_title>The COPENHAGEN Puberty Study</brief_title>
  <official_title>The COPENHAGEN Puberty Study Providing Normative Data of Healthy Danish Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ministry of Science, Technology and Innovation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By clinical examinations and withdrawing of blood samples from a large number of healthy
      Danish children, this study will reveal if age of pubertal onset is declining. Furthermore,
      the extensive normative data will provide detailed insight into normal ranges and individual
      changes of anthropometrics and hormone levels in healthy children during childhood and
      adolescence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The COPENHAGEN Puberty Study is a combined cross sectional and longitudinal study of healthy
      Danish children.

      All children will be thoroughly examined and blood- and urine samples will be collected at
      every visit. The families fill out questionaires.

      Physical examination: Height; sitting-height; weight; circumference of waist, hip, arm;
      measurement of fatfolds (biceps, triceps, flank, subscapularis); voice-break (yes/no), blood
      pressure; pubertal staging according to Tanners classification: breast development (B1-B5),
      genitalia development boys (G1-G5), pubic hair development (PH1-PH5), axillary hair (yes/no),
      sweat (yes/no), acne (yes/no

      Urine sample: For measurement of FSH, LH and endocrine disrupters.

      Blood sample: For measurement of hormone levels (FSH, LH, estradiol, SHBG, testosterone,
      DHEAS, androstenedione, inhibin A, inhibin B, Insl3, kisspeptin, ghrelin, leptin, IGF-1,
      IGFBP3, TSH, T4, Free T4, T3, HbA1C, calcium-ion, PTH, phosphate, 25-OH-vitamine D, AMH),
      endocrine disrupters (PCB´s, dioxines, parabens, phthalates), isolation of DNA and RNA to
      evaluate relevant polymorphisms.

      Questionaire: regarding information of previous growth and health.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2006</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pubertal Onset</measure>
    <time_frame>up to 8 year period.</time_frame>
    <description>Pubertal onset (according to Tanner stageing - Marshall &amp; Tanner 1969 and 1970), i.e. Tanner stages B2+ or G2+ [Tanner stages included genital stages 1-5 as well as pubic hairs tages 1-6]
Data of both arms were pooled for calculation of means.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1957</enrollment>
  <condition>Puberty</condition>
  <arm_group>
    <arm_group_label>Cross- sectional cohort</arm_group_label>
    <description>Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate. 1864 (1097 girls and 767 boys) (age 5.6-20.0 years) were included, resulting in an overall participation-rate of 30%. Blood samples were drawn, and a thorough clinical examination was performed in all participating children</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Longitudinal cohort</arm_group_label>
    <description>209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months. In july 2011, the mean (range) number of examinations per child was 7 (2-10).
116 (63 boys and 53 girls) continued from the cross sectional study to the longitudinal study. Thus, the total number of participants in The COPENHAGEN Puberty Study was 2020 children.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, white cells, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In the cross sectional study, all children at randomly selected schools in Copenhagen were
        invited (6203 children). 1864 accepted to participate.

        In the longitudinal study, children at two schools with the highest participating rate were
        invited to participate in the follow-up study. Ongoing recruitment was continued until at
        least 100 boys and 100 girls were enrolled in the logitudinal study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all children accepting to participate were included

        Exclusion Criteria:

          -  no children were excluded from examination or blood sampling. In case of chronic
             diseases, medical treatment, or ethnicity the children may be excluded from specific
             final data analysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Juul, PhD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, dept. of Growth and Reproduction</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Growth and Reproduction, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Courant F, Aksglaede L, Antignac JP, Monteau F, Sorensen K, Andersson AM, Skakkebaek NE, Juul A, Bizec BL. Assessment of circulating sex steroid levels in prepubertal and pubertal boys and girls by a novel ultrasensitive gas chromatography-tandem mass spectrometry method. J Clin Endocrinol Metab. 2010 Jan;95(1):82-92. doi: 10.1210/jc.2009-1140. Epub 2009 Nov 20.</citation>
    <PMID>19933393</PMID>
  </reference>
  <results_reference>
    <citation>Aksglaede L, Sørensen K, Petersen JH, Skakkebaek NE, Juul A. Recent decline in age at breast development: the Copenhagen Puberty Study. Pediatrics. 2009 May;123(5):e932-9. doi: 10.1542/peds.2008-2491.</citation>
    <PMID>19403485</PMID>
  </results_reference>
  <results_reference>
    <citation>Sørensen K, Aksglaede L, Petersen JH, Juul A. Recent changes in pubertal timing in healthy Danish boys: associations with body mass index. J Clin Endocrinol Metab. 2010 Jan;95(1):263-70. doi: 10.1210/jc.2009-1478. Epub 2009 Nov 19.</citation>
    <PMID>19926714</PMID>
  </results_reference>
  <results_reference>
    <citation>Sørensen K, Aksglaede L, Munch-Andersen T, Aachmann-Andersen NJ, Petersen JH, Hilsted L, Helge JW, Juul A. Sex hormone-binding globulin levels predict insulin sensitivity, disposition index, and cardiovascular risk during puberty. Diabetes Care. 2009 May;32(5):909-14. doi: 10.2337/dc08-1618. Epub 2009 Feb 5.</citation>
    <PMID>19196890</PMID>
  </results_reference>
  <results_reference>
    <citation>Juul A, Sørensen K, Aksglaede L, Garn I, Rajpert-De Meyts E, Hullstein I, Hemmersbach P, Ottesen AM. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys. J Clin Endocrinol Metab. 2009 Mar;94(3):1005-11. doi: 10.1210/jc.2008-1984. Epub 2008 Dec 16.</citation>
    <PMID>19088161</PMID>
  </results_reference>
  <results_reference>
    <citation>Sørensen K, Aksglaede L, Munch-Andersen T, Aachmann-Andersen NJ, Leffers H, Helge JW, Hilsted L, Juul A. Impact of the growth hormone receptor exon 3 deletion gene polymorphism on glucose metabolism, lipids, and insulin-like growth factor-I levels during puberty. J Clin Endocrinol Metab. 2009 Aug;94(8):2966-9. doi: 10.1210/jc.2009-0313. Epub 2009 May 5.</citation>
    <PMID>19417039</PMID>
  </results_reference>
  <results_reference>
    <citation>Sørensen K, Aksglaede L, Petersen JH, Leffers H, Juul A. The exon 3 deleted growth hormone receptor gene is associated with small birth size and early pubertal onset in healthy boys. J Clin Endocrinol Metab. 2010 Jun;95(6):2819-26. doi: 10.1210/jc.2009-2484. Epub 2010 Apr 9.</citation>
    <PMID>20382688</PMID>
  </results_reference>
  <results_reference>
    <citation>Sørensen K, Mouritsen A, Mogensen SS, Aksglaede L, Juul A. Insulin sensitivity and lipid profiles in girls with central precocious puberty before and during gonadal suppression. J Clin Endocrinol Metab. 2010 Aug;95(8):3736-44. doi: 10.1210/jc.2010-0731. Epub 2010 May 19.</citation>
    <PMID>20484471</PMID>
  </results_reference>
  <results_reference>
    <citation>Hagen CP, Aksglaede L, Sørensen K, Main KM, Boas M, Cleemann L, Holm K, Gravholt CH, Andersson AM, Pedersen AT, Petersen JH, Linneberg A, Kjaergaard S, Juul A. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab. 2010 Nov;95(11):5003-10. doi: 10.1210/jc.2010-0930. Epub 2010 Aug 18.</citation>
    <PMID>20719830</PMID>
  </results_reference>
  <results_reference>
    <citation>Aksglaede L, Sørensen K, Boas M, Mouritsen A, Hagen CP, Jensen RB, Petersen JH, Linneberg A, Andersson AM, Main KM, Skakkebæk NE, Juul A. Changes in anti-Müllerian hormone (AMH) throughout the life span: a population-based study of 1027 healthy males from birth (cord blood) to the age of 69 years. J Clin Endocrinol Metab. 2010 Dec;95(12):5357-64. doi: 10.1210/jc.2010-1207. Epub 2010 Sep 15.</citation>
    <PMID>20843948</PMID>
  </results_reference>
  <results_reference>
    <citation>Mogensen SS, Aksglaede L, Mouritsen A, Sørensen K, Main KM, Gideon P, Juul A. Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty. J Clin Endocrinol Metab. 2011 May;96(5):1393-401. doi: 10.1210/jc.2010-2745. Epub 2011 Feb 23.</citation>
    <PMID>21346077</PMID>
  </results_reference>
  <results_reference>
    <citation>Aksglaede L, Christiansen P, Sørensen K, Boas M, Linneberg A, Main KM, Andersson AM, Skakkebaek NE, Juul A. Serum concentrations of Anti-Müllerian Hormone (AMH) in 95 patients with Klinefelter syndrome with or without cryptorchidism. Acta Paediatr. 2011 Jun;100(6):839-45. doi: 10.1111/j.1651-2227.2011.02148.x. Epub 2011 Feb 25.</citation>
    <PMID>21251056</PMID>
  </results_reference>
  <results_reference>
    <citation>Frederiksen H, Aksglaede L, Sorensen K, Nielsen O, Main KM, Skakkebaek NE, Juul A, Andersson AM. Bisphenol A and other phenols in urine from Danish children and adolescents analyzed by isotope diluted TurboFlow-LC-MS/MS. Int J Hyg Environ Health. 2013 Nov;216(6):710-20. doi: 10.1016/j.ijheh.2013.01.007. Epub 2013 Mar 13.</citation>
    <PMID>23491025</PMID>
  </results_reference>
  <results_reference>
    <citation>Mouritsen A, Hagen CP, Sørensen K, Aksglaede L, Mieritz MG, Main KM, Almstrup K, Rajpert-De Meyts E, Juul A. Androgen receptor CAG repeat length is associated with body fat and serum SHBG in boys: a prospective cohort study. J Clin Endocrinol Metab. 2013 Mar;98(3):E605-9. doi: 10.1210/jc.2012-3778. Epub 2013 Feb 7.</citation>
    <PMID>23393169</PMID>
  </results_reference>
  <results_reference>
    <citation>Mouritsen A, Aksglaede L, Soerensen K, Hagen CP, Petersen JH, Main KM, Juul A. The pubertal transition in 179 healthy Danish children: associations between pubarche, adrenarche, gonadarche, and body composition. Eur J Endocrinol. 2012 Dec 31;168(2):129-36. doi: 10.1530/EJE-12-0191. Print 2013 Feb.</citation>
    <PMID>23093700</PMID>
  </results_reference>
  <results_reference>
    <citation>Hilsted L, Rustad P, Aksglæde L, Sørensen K, Juul A. Recommended Nordic paediatric reference intervals for 21 common biochemical properties. Scand J Clin Lab Invest. 2013 Feb;73(1):1-9. doi: 10.3109/00365513.2012.721519. Epub 2012 Sep 26. Erratum in: Scand J Clin Lab Invest. 2013 Dec;73(8):661.</citation>
    <PMID>23013046</PMID>
  </results_reference>
  <results_reference>
    <citation>Mieritz MG, Frederiksen H, Sørensen K, Aksglaede L, Mouritsen A, Hagen CP, Skakkebaek NE, Andersson AM, Juul A. Urinary phthalate excretion in 555 healthy Danish boys with and without pubertal gynaecomastia. Int J Androl. 2012 Jun;35(3):227-35. doi: 10.1111/j.1365-2605.2012.01279.x.</citation>
    <PMID>22612475</PMID>
  </results_reference>
  <results_reference>
    <citation>Frederiksen H, Sørensen K, Mouritsen A, Aksglaede L, Hagen CP, Petersen JH, Skakkebaek NE, Andersson AM, Juul A. High urinary phthalate concentration associated with delayed pubarche in girls. Int J Androl. 2012 Jun;35(3):216-26. doi: 10.1111/j.1365-2605.2012.01260.x. Epub 2012 Mar 19.</citation>
    <PMID>22428786</PMID>
  </results_reference>
  <results_reference>
    <citation>Hagen CP, Aksglaede L, Sørensen K, Mouritsen A, Andersson AM, Petersen JH, Main KM, Juul A. Individual serum levels of anti-Müllerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum Reprod. 2012 Mar;27(3):861-6. doi: 10.1093/humrep/der435. Epub 2012 Jan 2.</citation>
    <PMID>22215627</PMID>
  </results_reference>
  <results_reference>
    <citation>Busch AS, Hagen CP, Main KM, Pereira A, Corvalan C, Almstrup K, Mericq V, Juul A. Genetic Variation of Follicle-Stimulating Hormone Action Is Associated With Age at Testicular Growth in Boys. J Clin Endocrinol Metab. 2017 May 1;102(5):1740-1749. doi: 10.1210/jc.2016-4013.</citation>
    <PMID>28323923</PMID>
  </results_reference>
  <results_reference>
    <citation>Busch AS, Hagen CP, Almstrup K, Juul A. Circulating MKRN3 Levels Decline During Puberty in Healthy Boys. J Clin Endocrinol Metab. 2016 Jun;101(6):2588-93. doi: 10.1210/jc.2016-1488. Epub 2016 Apr 8.</citation>
    <PMID>27057785</PMID>
  </results_reference>
  <results_reference>
    <citation>Almstrup K, Lindhardt Johansen M, Busch AS, Hagen CP, Nielsen JE, Petersen JH, Juul A. Pubertal development in healthy children is mirrored by DNA methylation patterns in peripheral blood. Sci Rep. 2016 Jun 28;6:28657. doi: 10.1038/srep28657. Erratum in: Sci Rep. 2016 Aug 03;6:30664.</citation>
    <PMID>27349168</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <results_first_submitted>April 25, 2017</results_first_submitted>
  <results_first_submitted_qc>September 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2019</results_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Anders Juul</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hormones</keyword>
  <keyword>Endocrine Disrupters</keyword>
  <keyword>Polymorphism, Genetic</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Cross-sectional study: All pupils at 10 different schools in the Copenhagen area were invited to participate.
Longitudinal study: All pupils from 2 of the 10 schools were invited to participate in the follow up study. This includes pupils that have been recruited to the cross-sectional part. (see footnote)</recruitment_details>
      <pre_assignment_details>No participants were excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cross- Sectional Cohort</title>
          <description>Schools were randomly selected. Blood samples were drawn, and a thorough clinical examination was performed in all participating children</description>
        </group>
        <group group_id="P2">
          <title>Longitudinal Cohort</title>
          <description>Healthy Danish children were examined and blood samples were drawn every 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1864"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1864"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cross- Sectional Cohort</title>
          <description>Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate. 1864 (1097 girls and 767 boys) (age 5.6-20.0 years) were included, resulting in an overall participation-rate of 30%. Blood samples were drawn, and a thorough clinical examination was performed in all participating children</description>
        </group>
        <group group_id="B2">
          <title>Longitudinal Cohort</title>
          <description>209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months. In july 2011, the mean (range) number of examinations per child was 7 (2-10).
116 (63 boys and 53 girls) continued from the cross sectional study to the longitudinal study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1748"/>
            <count group_id="B2" value="209"/>
            <count group_id="B3" value="1957"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1748"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="1957"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.8" lower_limit="5.6" upper_limit="20"/>
                    <measurement group_id="B2" value="11.8" lower_limit="5.6" upper_limit="20"/>
                    <measurement group_id="B3" value="11.8" lower_limit="5.6" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1044"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="1152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="704"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1748"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="1957"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1748"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pubertal Onset</title>
        <description>Pubertal onset (according to Tanner stageing - Marshall &amp; Tanner 1969 and 1970), i.e. Tanner stages B2+ or G2+ [Tanner stages included genital stages 1-5 as well as pubic hairs tages 1-6]
Data of both arms were pooled for calculation of means.</description>
        <time_frame>up to 8 year period.</time_frame>
        <population>Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cross- Sectional Cohort</title>
            <description>Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate (overall participation-rate: 30%). Blood samples were drawn, and a thorough clinical examination was performed in all participating children</description>
          </group>
          <group group_id="O2">
            <title>Longitudinal Cohort</title>
            <description>209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Pubertal Onset</title>
          <description>Pubertal onset (according to Tanner stageing - Marshall &amp; Tanner 1969 and 1970), i.e. Tanner stages B2+ or G2+ [Tanner stages included genital stages 1-5 as well as pubic hairs tages 1-6]
Data of both arms were pooled for calculation of means.</description>
          <population>Population</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1748"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Girls</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.86" lower_limit="9.70" upper_limit="10.01"/>
                    <measurement group_id="O2" value="9.86" lower_limit="9.70" upper_limit="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Boys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.66" lower_limit="11.49" upper_limit="11.82"/>
                    <measurement group_id="O2" value="11.66" lower_limit="11.49" upper_limit="11.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years</time_frame>
      <desc>No serious and/or other adverse events did occur</desc>
      <group_list>
        <group group_id="E1">
          <title>Population</title>
          <description>This is a descriptive study elucidating normal variation. Therefore, the study population is not grouped</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1957"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1957"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1957"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anders Juul</name_or_title>
      <organization>Rigshospitalet</organization>
      <phone>+45 3545 5085</phone>
      <email>Anders.Juul@regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

